RenovoRx (RNXT) investor relations material

Executive summary

• Achieved all three major milestones: record Q2 2026 revenue of $909,000, accelerated commercial center activation, and first use of RenovoCath in a non-pancreatic solid tumor (sarcoma), highlighting physician-driven adoption.

• Revenue growth driven by increased commercial execution, expanding customer pipeline, and expansion into new tumor indications.

• Increased 2026 annual revenue guidance to $3.75M–$4.25M, reflecting strong first-half performance and robust commercial pipeline.

• Phase III TIGER-PaC trial reached full enrollment; completion expected in H1 2027 with topline data in H2 2027.

• Physician-driven expansion and strong repeat orders signal growing adoption and satisfaction.

Financial highlights

• Q2 2026 revenue reached $909,000, up 61% sequentially and 115% year-over-year.

• Gross profit was $766,000 with a gross margin of ~84%.

• Net loss per share improved to $0.06 from $0.08 year-over-year and $0.09 sequentially; net loss was $2.9M.

• Cash and equivalents stood at $9.5 million at quarter end, expected to fund operations into H2 2027.

• Non-GAAP net loss: $2.34M, reflecting adjustments for share-based compensation.

Outlook and guidance

• Full-year 2026 revenue guidance raised to $3.75–$4.25 million, implying 241%–286% year-over-year growth.

• Targeting 36+ active commercial centers by year-end 2026.

• Break-even operations anticipated in Q4 2027, with a $5 million quarterly revenue run rate as the target.

• Q3 revenue expected to exceed Q2, continuing record-setting trend.